Glenmark USA launches epinephrine injection multiple-dose vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose vial on December 23, 2025. This new product is bioequivalent and therapeutically equivalent to the reference listed drug, epinephrine injection USP, 30 mg/30 mL (1 mg/mL) by BPI Labs, LLC.

According to IQVIA sales data for the 12-month period ending October 2025, the market for epinephrine injection USP, 30 mg/30 mL (1 mg/mL) achieved annual sales of approximately $67.6 million. Marc Kikuchi, president and business head, North America, stated that this launch enhances Glenmark's product portfolio within the institutional channel and reinforces its commitment to providing quality and affordable alternatives for patients.

Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with a presence across branded, generics, and over-the-counter segments, focusing on respiratory, dermatology, and oncology. The company operates 11 manufacturing facilities across four continents and in over 80 countries, recognized among the top 100 biopharmaceutical companies by pharmaceutical sales in 2023.